People on Ozempic and other GLP-1 agonist drugs commonly report they no longer have constant, incessant thoughts about food. This is how the drugs work.

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Free Report) is anticipated to announce its earnings results on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.89) per share ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon ... oxyntomodulin analog (OPK-88006) with ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Zealand and Roche will co-develop and co-commercialise Zealand’s amylin analogue petrelintide as a monotherapy, and in ...